Detalhe da pesquisa
1.
Risk factors for severe immune-related adverse events after first-line pembrolizumab monotherapy or combination chemotherapy for non-small-cell lung cancer.
Invest New Drugs
; 40(6): 1298-1305, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36227514
2.
Transbronchial cryobiopsy for small peripheral pulmonary lesions using endobronchial ultrasonography and an ultrathin bronchoscope.
Respir Investig
; 62(1): 77-84, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37976917
3.
Risk factors for severe immune-related pneumonitis after nivolumab plus ipilimumab therapy for non-small cell lung cancer.
Thorac Cancer
; 2024 Jun 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38828610
4.
Severe heart failure due to peripartum cardiomyopathy.
Respirol Case Rep
; 11(5): e01137, 2023 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-37051303
5.
Pneumocystis Pneumonia Infection Following the Initiation of Pembrolizumab Therapy for Lung Adenocarcinoma.
Intern Med
; 62(22): 3381-3385, 2023 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37005268
6.
Cytokine release syndrome in a patient with non-small cell lung cancer on ipilimumab and nivolumab maintenance therapy after vaccination with the mRNA-1273 vaccine: a case report.
Transl Lung Cancer Res
; 11(9): 1973-1976, 2022 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-36248324
7.
Diffuse large B-cell lymphoma with cardiac invasion diagnosed using transesophageal ultrasound-guided bronchoscopic aspiration.
Respirol Case Rep
; 10(9): e01022, 2022 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-35992555
8.
Hemothorax as a complication of transbronchial lung cryobiopsy.
Respirol Case Rep
; 10(10): e01034, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-36090021
9.
Tumor-Associated Raynaud's Phenomenon Exacerbated by Administration of Immune Checkpoint Inhibitors.
J Thorac Oncol
; 17(10): 1233-1234, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36192079